Rhythm Pharmaceuticals Q3 2026 Earnings Conference Call - RHYTHM PHARMACEUTICALS INC

Financial Performance:

• Q3 2026 total revenue reached $92.1 million, representing 29% sequential growth from Q2 and 67.5% generated from the U.S. market.
• U.S. acquired Hypothalamic Obesity (HO) product demand was the primary driver of growth, with 20% sequential increase in reimbursed patients globally.
• Cost of Goods Sold (COGS) stood at 13.2% of product revenue, driven by materials and royalties; R&D expenses were $52.5 million (up from $46M YoY) due to personnel and Bivomelagon development; SG&A was $66.8 million.
• Net loss was $61 million ($0.61 per share); cash used in operations was approximately $3 million.
• Company ended the quarter with $321 million in cash, cash equivalents, and short-term investments, sufficient to fund operations for at least 24 months without loan proceeds.

Guidance and Future Outlook:

• Full-year 2026 non-GAAP operating expenses guidance updated to $360–$380 million; R&D guidance midpoint reduced by $15 million to $165–$175 million due to shifting formulation activities to 2027.
• Commercial outlook anticipates Japan becoming the second-largest market; first-year Japan launch constrained by two-week supply limits, expected to accelerate in years 2–3 upon removal of restrictions in late 2027.
• Europe launches targeted for 2027, starting with Germany; Germany's GBA process nearing completion, with reimbursement dossiers filed in major markets.
• Strategic focus on 2027 for full disclosure of next-generation MC4R portfolio and initiation of PWS Phase 3 trials.

Business Segments and Product Lines:

• Imcivree (Setmelanotide) for Acquired HO: Strong Q3 launch momentum with >700 start forms received; 500+ prescribers engaged (200 new in Q3); 75% of approvals obtained via prior authorization within 60 days.
• Imcivree for Bardet-Biedl Syndrome (BBS): Continued growth in Q3 with dedicated territory managers; serves as a key revenue contributor alongside HO.
• Vivomelagon (Bivomelagon): Phase 3 study for Acquired HO initiated (52 weeks, BMI primary endpoint); first patients dosed January 2027; PWS Phase 3 study (6 months, hyperphagia primary endpoint) planned to start in 2027.
• License Amendment: Amended agreement with LG Chem to reduce cross-portfolio royalty from 5–7% to 1% flat for U.S. Bivomelagon approval; company pays $350 million in installments over four years and assumes $200 million commercial milestone upon $3B annual sales.

Market and Competitive Landscape:

• Acquired HO market characterized by significant unmet need, estimated 5,000–8,000 patients in Japan and ~10,000 in Europe; distinct from genetic disorders as diagnosis relies on clinical history of CNS injury.
• Japan launch leverages established disease guidelines from the Japanese Endocrine Society; high concentration of patients in brain tumor centers facilitates identification.
• Competitive landscape includes Nurocrine's BICAT (approved for Prader-Willi) and Vertex's historical CF approach; Rhythm differentiates via oral administration (Vivomelagon vs. injectables) and lack of hyperpigmentation.
• Rhythm expects to build a sustainable market position with potential for combination therapies in Prader-Willi similar to Vertex's strategy in Cystic Fibrosis.

Risks and Challenges:

• Japan Launch Constraints: Initial two-week prescription supply limits (until Nov 2027) will delay full commercial ramp-up and increase patient burden.
• Diagnostic Complexity: Acquired HO requires clinical diagnosis based on injury history rather than genetic testing, necessitating extensive physician education to identify patients.
• Regulatory Path: PWS Phase 3 design relies on precedent set by BICAT; FDA acceptance of 6-month hyperphagia trials vs. 12-month BMI trials remains a variable.
• Payer Access: While progress is strong, obtaining national coverage policies in Europe remains a sequential, country-specific process.

Management Commentary and Tone:

• Tone is highly confident and bullish, with management describing the Q3 results as a "strong start" and the LG Chem amendment as a "bullish investment."
• CEO David Meeker emphasized the strategic importance of Prader-Willi, drawing parallels to Vertex's dominance in Cystic Fibrosis.
• Management expressed satisfaction with payer access speed, noting it is quicker than the BBS launch, and highlighted the alignment of interests with LG Chem via the amended royalty structure.
• CFO Hunter Smith confirmed the balance sheet is strengthened by the $750 million term loan facility (drawing $250 million initially) and favorable covenants.

Analyst Questions and Answers:

• Patient Dynamics: Management expects steady, sustainable uptake without immediate acceleration, citing the time required for physician education and diagnosis confirmation; no month-over-month start form breakdowns provided but Q4 momentum held.
• Payer Mix: Initial AHO patient payer mix resembles BBS (majority commercial), though slightly more commercial than Medicaid; seasonality expected in Q1 due to insurance changes.
• Retention: Early retention data is strong; management anticipates potentially higher retention than BBS due to patient familiarity with injectables and clear efficacy data.
• PWS Study Design: Primary endpoint confirmed as hyperphagia (HDCQ) over 6 months to accelerate approval; BMI will be a secondary endpoint; 12-month data likely required for future label expansion.
• Japan Pricing: Public price set at $2,200 per vial (60% of U.S. WAC); price fixed for 10 years with standard capping mechanisms.
• LG Chem Deal Economics: Deal driven by confidence in AHO switch potential and PWS future upside; 5% royalty reduction yields quick payback against risk-adjusted consensus.
• Diagnostics: Unlike BBS, Rhythm provides education rather than genetic testing support for AHO, as the condition is identified via clinical phenotype (brain injury + weight gain).

Other Key Points:

• Japan launched Imcivree on October 14, less than 6 months after U.S. approval, with 1,000+ patients identified pre-launch.
• Patent protection for Bivomelagon and 718 extends into the 2040s, ensuring long-term IP value.
• The company completed critical supporting studies for Vivomelagon (bioequivalence, food effect, drug-drug interaction, hepatic impairment) to de-risk Phase 3 trials.
• Management plans to provide a comprehensive portfolio update in 2027, including combination therapy strategies for MC4R diseases.